AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22173281 — intervention group
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine XR (50 mg/day for 10 days)
Number of subjects: 24
Study 22173281 — intervention group
Group type: COMPARATOR
Intervention: Indinavir (800 mg) co-administered on day 12
Number of subjects: 24
Study 20460139 — intervention group
Group type: EXPERIMENTAL
Intervention: Study pairs that later served as Old pairs
Number of subjects: 0
Study 20460139 — intervention group
Group type: EXPERIMENTAL
Intervention: Study pairs containing words that subsequently appeared in Intra pairs
Number of subjects: 0
Study 20460139 — intervention group
Group type: EXPERIMENTAL
Intervention: Accepted Old pairs
Number of subjects: 0
Study 20460139 — intervention group
Group type: EXPERIMENTAL
Intervention: Rejected Intra pairs
Number of subjects: 0
Study 17601187 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral subthalamic nucleus (STN) stimulation ON
Number of subjects: 0
Study 17601187 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral subthalamic nucleus (STN) stimulation ON
Number of subjects: 0
Study 17601187 — intervention group
Group type: COMPARATOR
Intervention: Basal stimulation OFF
Number of subjects: 0
Study 15582640 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitation intervention for implementing Kangaroo Mother Care guidelines
Number of subjects: 8
Study 15582640 — intervention group
Group type: COMPARATOR
Intervention: Control group with improvement-focused organizational culture
Number of subjects: 8
Study 15582640 — intervention group
Group type: EXPERIMENTAL
Intervention: Change team establishment
Number of subjects: 8
Study 15582640 — intervention group
Group type: EXPERIMENTAL
Intervention: Contextual factors (leadership, staff attitudes)
Number of subjects: 8
Study 15582640 — intervention group
Group type: EXPERIMENTAL
Intervention: Learning and behaviour change
Number of subjects: 8
Study 11853372 — intervention group
Group type: EXPERIMENTAL
Intervention: Monograph for growth disorders
Number of subjects: 336
Study 11853372 — intervention group
Group type: COMPARATOR
Intervention: Control group (nurses not receiving the monograph)
Number of subjects: 336
Study 10190404 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with metoprolol + felodipine
Number of subjects: 33
Study 10190404 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with enalaril + hydrochlorothiazide
Number of subjects: 33
Study 8547381 — intervention group
Group type: EXPERIMENTAL
Intervention: In-home visits with structured comprehensive geriatric assessment and follow-up by specially trained nurses
Number of subjects: 791
Study 2367393 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin 2 X 200 mg orally for 10 days
Number of subjects: 57
Study 2367393 — intervention group
Group type: COMPARATOR
Intervention: Established antibiotics
Number of subjects: 57
Study 2367393 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin
Number of subjects: 57
Study 31823115 — intervention group
Group type: EXPERIMENTAL
Intervention: ANCOVA with random assignment and multinormal covariates
Number of subjects: 0
Study 31823115 — intervention group
Group type: COMPARATOR
Intervention: Current ANOVA formula
Number of subjects: 0
Study 30315500 — intervention group
Group type: EXPERIMENTAL
Intervention: DBT training program
Number of subjects: 57
Study 30315500 — intervention group
Group type: COMPARATOR
Intervention: Standard care training program
Number of subjects: 57
Study 28232290 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized enhanced CBT
Number of subjects: 161
Study 28232290 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescent Community Reinforcement Approach (ACRA)
Number of subjects: 161
Study 28232290 — intervention group
Group type: COMPARATOR
Intervention: Motivational enhancement and cognitive behavioral therapy intervention (MET/CBT-7)
Number of subjects: 161
Study 25585069 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline prophylaxis
Number of subjects: 30
Study 25585069 — intervention group
Group type: COMPARATOR
Intervention: Contingency management (CM)
Number of subjects: 30
Study 23230311 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated soluble gp130 (fifth quintile versus all lower quintiles)
Number of subjects: 1452
Study 21119517 — intervention group
Group type: EXPERIMENTAL
Intervention: General anaesthesia combined with thoracic epidural block (group GT)
Number of subjects: 66
Study 21119517 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia (group GA)
Number of subjects: 66
Study 19822979 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial coverage (stent implantation for an occluded/culprit lesion only)
Number of subjects: 76
Study 19822979 — intervention group
Group type: COMPARATOR
Intervention: Full coverage (complete coverage of lesions)
Number of subjects: 76
Study 17110824 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine
Number of subjects: 0
Study 15174325 — intervention group
Group type: EXPERIMENTAL
Intervention: Mexicor (6-9 mg/kg/day) in combination with conventional treatment for unstable angina (UA)
Number of subjects: 338
Study 15174325 — intervention group
Group type: EXPERIMENTAL
Intervention: Mexicor (6-9 mg/kg/day) in combination with conventional treatment for acute myocardial infarction (MI)
Number of subjects: 338
Study 15174325 — intervention group
Group type: EXPERIMENTAL
Intervention: Mexicor (6-9 mg/kg/day) in combination with conventional treatment for hypertensive crises (HC)
Number of subjects: 338
Study 15174325 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment alone for unstable angina (UA)
Number of subjects: 338
Study 15174325 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment alone for acute myocardial infarction (MI)
Number of subjects: 338
Study 15174325 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment alone for hypertensive crises (HC)
Number of subjects: 338
Study 11697832 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine (GEM) 1000 mg/m2, days 1, 8 and 15
Number of subjects: 169
Study 11697832 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin (100 mg/m2, day 1) plus Vindesine (3 mg/m2, days 1 and 15) (PV)
Number of subjects: 169
Study 11697832 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin-vindesine (PV)
Number of subjects: 169
Study 9399372 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine 200 micrograms
Number of subjects: 30
Study 9399372 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine 400 micrograms
Number of subjects: 30
Study 9399372 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine 600 micrograms
Number of subjects: 30
Study 9399372 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam 5 mg
Number of subjects: 30
Study 9399372 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam 10 mg
Number of subjects: 30
Study 7517825 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular tramadol 100 mg
Number of subjects: 6
Study 7517825 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular tramadol 300 mg
Number of subjects: 6
Study 7517825 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 2897005 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsalva manoeuvre in the supine position
Number of subjects: 35
Study 2897005 — intervention group
Group type: EXPERIMENTAL
Intervention: Right carotid sinus massage
Number of subjects: 35
Study 2897005 — intervention group
Group type: EXPERIMENTAL
Intervention: Left carotid sinus massage
Number of subjects: 35
Study 2897005 — intervention group
Group type: EXPERIMENTAL
Intervention: Diving reflex
Number of subjects: 35
Study 2897005 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsalva manoeuvre while standing
Number of subjects: 35
Study 2897005 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical manoeuvres overall
Number of subjects: 35
Study 31901710 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol supplementation (50,000 IU weekly for 8 weeks)
Number of subjects: 52
Study 31901710 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol supplementation
Number of subjects: 52
Study 31901710 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 29175384 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged targeted temperature management (TTM) for 48 hours
Number of subjects: 115
Study 29175384 — intervention group
Group type: COMPARATOR
Intervention: Standard targeted temperature management (TTM) for 24 hours
Number of subjects: 115
Study 28382551 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg vitamin C + 235 mg vitamin E daily (AO)
Number of subjects: 33
Study 28382551 — intervention group
Group type: COMPARATOR
Intervention: Placebo (CG)
Number of subjects: 33
Study 28382551 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (AO and CG)
Number of subjects: 33
Study 25719419 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical dexamethasone associated with hyaluronic acid (group 3)
Number of subjects: 18
Study 25719419 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical dexamethasone (group 2)
Number of subjects: 18
Study 25719419 — intervention group
Group type: COMPARATOR
Intervention: Cochlear implantation (control group 1)
Number of subjects: 18
Study 23742777 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal local anesthesia (IPLA) with bupivacaine
Number of subjects: 41
Study 23742777 — intervention group
Group type: COMPARATOR
Intervention: Sham control with saline
Number of subjects: 41
Study 20731310 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y reconstruction
Number of subjects: 67
Study 20731310 — intervention group
Group type: COMPARATOR
Intervention: J-pouch reconstruction
Number of subjects: 67
Study 18986534 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg licofelone twice daily
Number of subjects: 355
Study 18986534 — intervention group
Group type: COMPARATOR
Intervention: 500 mg naproxen twice daily
Number of subjects: 355
Study 17034279 — intervention group
Group type: EXPERIMENTAL
Intervention: Verum acupuncture
Number of subjects: 1162
Study 17034279 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 1162
Study 17034279 — intervention group
Group type: COMPARATOR
Intervention: Guideline standard therapy
Number of subjects: 1162
Study 12514268 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 g of psyllium per day for 30 days
Number of subjects: 0
Study 12514268 — intervention group
Group type: COMPARATOR
Intervention: 0 g of psyllium per day for 30 days (control)
Number of subjects: 0
Study 10882617 — intervention group
Group type: EXPERIMENTAL
Intervention: PRO 542 (0.2-10 mg/kg)
Number of subjects: 0
Study 8891083 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (20 mg for the first week, 40 mg for the remaining period)
Number of subjects: 90
Study 8891083 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 1799283 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructose alone (50 g)
Number of subjects: 0
Study 1799283 — intervention group
Group type: COMPARATOR
Intervention: Glucose alone (50 g)
Number of subjects: 0
Study 1799283 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructose plus starch (50 g fructose + 15 g starch)
Number of subjects: 0
Study 6306506 — intervention group
Group type: EXPERIMENTAL
Intervention: IV mannitol
Number of subjects: 8
Study 6306506 — intervention group
Group type: EXPERIMENTAL
Intervention: IV furosemide
Number of subjects: 8
Study 31250552 — intervention group
Group type: EXPERIMENTAL
Intervention: Incomplete ART adherence (reported by 109 participants, 7%)
Number of subjects: 1627
Study 31250552 — intervention group
Group type: EXPERIMENTAL
Intervention: Exploratory analysis for SAA
Number of subjects: 1627
Study 31250552 — intervention group
Group type: COMPARATOR
Intervention: Complete ART adherence (100%)
Number of subjects: 1627
Study 29363988 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week brisk walking training (60-min of brisk walking, three times a week for a total of 12 weeks)
Number of subjects: 46
Study 29363988 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week brisk walking training
Number of subjects: 46
Study 29363988 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 46
Study 26928137 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender-based motivational interviewing (GBMI)
Number of subjects: 35
Study 26928137 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control
Number of subjects: 35
Study 25258143 — intervention group
Group type: EXPERIMENTAL
Intervention: Nuclear-Family cohort
Number of subjects: 914
Study 25258143 — intervention group
Group type: EXPERIMENTAL
Intervention: Twins cohort
Number of subjects: 914
Study 25258143 — intervention group
Group type: COMPARATOR
Intervention: Environmental factors
Number of subjects: 914
Study 23059357 — intervention group
Group type: EXPERIMENTAL
Intervention: Single 0.5 mL dose of virosomal subunit influenza vaccine (Inflexal V)
Number of subjects: 205
Study 23059357 — intervention group
Group type: COMPARATOR
Intervention: Standard two 0.25 mL doses given four weeks apart
Number of subjects: 205
Study 23059357 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 205
Study 20147716 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin B (10 mg/kg body weight, single infusion)
Number of subjects: 412
Study 20147716 — intervention group
Group type: COMPARATOR
Intervention: Amphotericin B deoxycholate (1 mg/kg, 15 infusions every other day during a 29-day hospitalization)
Number of subjects: 412
Study 20147716 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin B
Number of subjects: 412
Study 20147716 — intervention group
Group type: COMPARATOR
Intervention: Amphotericin B deoxycholate
Number of subjects: 412
Study 20147716 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 412
Study 17980416 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 microg budesonide + 9 microg formoterol (twice daily, 100 microg per dose; n = 20)
Number of subjects: 100
Study 17980416 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 microg budesonide + 5 or 10 mg montelukast (once daily at bedtime; n = 20)
Number of subjects: 100
Study 17980416 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 or 10 mg montelukast (n = 20)
Number of subjects: 100
Study 17980416 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 microg budesonide (n = 20)
Number of subjects: 100
Study 17980416 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 20)
Number of subjects: 100
Study 16751933 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin (40 mg/day)
Number of subjects: 75
Study 16751933 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated Heparin (UH) (5,000 IU t.i.d.)
Number of subjects: 75
Study 14521593 — intervention group
Group type: EXPERIMENTAL
Intervention: Ximelagatran 24 mg bid
Number of subjects: 1838
Study 14521593 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin 30 mg bid
Number of subjects: 1838
Study 10413638 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive medical therapy including bedrest, anti-ischaemic medications, aspirin, and heparin.
Number of subjects: 733
Study 8673551 — intervention group
Group type: EXPERIMENTAL
Intervention: Interest in participating in HIV preventive vaccine trials
Number of subjects: 630
Study 8673551 — intervention group
Group type: EXPERIMENTAL
Intervention: Older men
Number of subjects: 630
Study 8673551 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived peer willingness to enroll in vaccine trials
Number of subjects: 630
Study 8673551 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimism about success in vaccine development
Number of subjects: 630
Study 8673551 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment setting (community settings vs. college campuses)
Number of subjects: 630
Study 8673551 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine‐induced seroconversion
Number of subjects: 630
Study 1765571 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam (0.25 or 0.50 mg)
Number of subjects: 15
Study 1765571 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 6136690 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxycillin
Number of subjects: 52
Study 6136690 — intervention group
Group type: EXPERIMENTAL
Intervention: Cephradine
Number of subjects: 52
Study 6136690 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 52
Study 28884296 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisphosphonate therapy (pamidronate and zoledronic acid, mean 2.95 infusions per patient)
Number of subjects: 23
Study 28884296 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisphosphonate therapy
Number of subjects: 23
Study 28913643 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin (24 IU intranasal)
Number of subjects: 78
Study 28913643 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study 25636503 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (real) + Transcutaneous electrical nerve stimulation (real)
Number of subjects: 92
Study 25636503 — intervention group
Group type: COMPARATOR
Intervention: Transcranial direct current stimulation (sham) + Transcutaneous electrical nerve stimulation (sham)
Number of subjects: 92
Study 25636503 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (real) + Transcutaneous electrical nerve stimulation (sham)
Number of subjects: 92
Study 25636503 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (sham) + Transcutaneous electrical nerve stimulation (real)
Number of subjects: 92
Study 23298790 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency rTMS (10Hz)
Number of subjects: 27
Study 23298790 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-frequency rTMS (1Hz)
Number of subjects: 27
Study 23298790 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 27
Study 21178077 — intervention group
Group type: EXPERIMENTAL
Intervention: Cereal L fortified with electrolytic iron (54.5 mg iron/100 g cereal)
Number of subjects: 95
Study 21178077 — intervention group
Group type: EXPERIMENTAL
Intervention: Cereal M fortified with ferrous fumarate (52.2 mg Fe/100 g)
Number of subjects: 95
Study 18280335 — intervention group
Group type: EXPERIMENTAL
Intervention: MAL‐LPDL
Number of subjects: 15
Study 18280335 — intervention group
Group type: COMPARATOR
Intervention: LPDL
Number of subjects: 15
Study 16996833 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 0
Study 16996833 — intervention group
Group type: EXPERIMENTAL
Intervention: Abciximab
Number of subjects: 0
Study 16996833 — intervention group
Group type: EXPERIMENTAL
Intervention: Half-dose TNK with abciximab and reduced-dose UFH
Number of subjects: 0
Study 16996833 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenecteplase (TNK) with enoxaparin or abciximab
Number of subjects: 0
Study 16996833 — intervention group
Group type: COMPARATOR
Intervention: Standard UFH
Number of subjects: 0
Study 12679443 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment at a dosage of 0.067 mg/kg.d until attainment of adult height
Number of subjects: 168
Study 12679443 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 168
Study 11782853 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol IR 50 mg 3 times daily
Number of subjects: 15
Study 11782853 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol CR/XL 100 mg once daily
Number of subjects: 15
Study 11782853 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol CR/XL 200 mg once daily
Number of subjects: 15
Study 9386657 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (0.2 mg/kg)
Number of subjects: 16
Study 9386657 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen (10 mg/kg)
Number of subjects: 16
Study 9386657 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin and Ibuprofen (both treatments)
Number of subjects: 16
Study 7904762 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluphenazine (FPZ) 20 mg/day
Number of subjects: 156
Study 7904762 — intervention group
Group type: COMPARATOR
Intervention: Fluphenazine (FPZ) 80 mg/day
Number of subjects: 156
Study 7904762 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol 20 mg/day
Number of subjects: 156
Study 7904762 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluphenazine (FPZ) 20 mg/day (open phase)
Number of subjects: 156
Study 3586115 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress inoculation training
Number of subjects: 20
Study 3586115 — intervention group
Group type: COMPARATOR
Intervention: No training (control group)
Number of subjects: 20
Study 3586115 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (stress inoculation and control)
Number of subjects: 20
Study 3586115 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-report measures
Number of subjects: 20
Study 3586115 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart rate monitoring
Number of subjects: 20
Study 29148929 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol-Wise (version 4.0, 3rd Millennium Classrooms) administered prior to first semester
Number of subjects: 76
Study 29148929 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control (received Alcohol-Wise second semester)
Number of subjects: 76
Study 27568507 — intervention group
Group type: EXPERIMENTAL
Intervention: MET + Family Check-Up (FCU)
Number of subjects: 97
Study 27568507 — intervention group
Group type: COMPARATOR
Intervention: adolescent MET-only
Number of subjects: 97
Study 27568507 — intervention group
Group type: EXPERIMENTAL
Intervention: Older adolescents
Number of subjects: 97
Study 25138685 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain on Movement (POM) questionnaire
Number of subjects: 482
Study 25138685 — intervention group
Group type: COMPARATOR
Intervention: Pain at rest on VAS
Number of subjects: 482
Study 25138685 — intervention group
Group type: COMPARATOR
Intervention: Neck Disability Index (NDI)
Number of subjects: 482
Study 25138685 — intervention group
Group type: COMPARATOR
Intervention: Short-form 36 health survey questionnaire (SF-36)
Number of subjects: 482
Study 25138685 — intervention group
Group type: COMPARATOR
Intervention: Range of motion
Number of subjects: 482
Study 23867222 — intervention group
Group type: EXPERIMENTAL
Intervention: Pocket PATH (Personal Assistant for Tracking Health)
Number of subjects: 0
Study 21346067 — intervention group
Group type: COMPARATOR
Intervention: Placebo (group A, n = 32)
Number of subjects: 95